Activest Wealth Management’s Karyopharm Therapeutics KPTI Stock Holding History

Activest Wealth Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$81	Hold	66	–	–	﹤0.01%	1015
2026 Q2	$645	Hold	66	–	–	﹤0.01%	1022
2026 Q1	$368	Hold	66	–	–	﹤0.01%	1093
2025 Q4	$486	Hold	66	–	–	﹤0.01%	1001
2025 Q3	$432	Hold	66	–	–	﹤0.01%	975
2025 Q2	$284	Hold	66	–	–	﹤0.01%	939
2025 Q1	$247	Sell	66 -1	-1%	-$9	﹤0.01%	922
2024 Q4	$676	Hold	67	–	–	﹤0.01%	499
2024 Q3	$830	Hold	67	–	–	﹤0.01%	468
2024 Q2	$868	Buy	+67	New	+$1.11K	﹤0.01%	443

Other funds holding KPTI

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Owl Creek Wealth Partners Denver, Colorado $355M AUM

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

MB, Levis & Associates Center Valley, Pennsylvania $273M AUM 8.08% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Activest Wealth Management's KPTI Position: Q3 2026 in Review

Activest Wealth Management held its Karyopharm Therapeutics (KPTI) position steady in Q3 2026 at 66 shares worth $81. The position accounts for ﹤0.01% of the portfolio, ranked #1015.

Activest Wealth Management first reported a position in KPTI in Q2 2024 and has held it in 10 quarters since. The position peaked at $868 in Q2 2024. 13 funds tracked by Wall St. Rank hold KPTI as of Q3 2026.

Activest Wealth Management held 66 shares of Karyopharm Therapeutics worth $81 as of Q3 2026.
Activest Wealth Management left its Karyopharm Therapeutics share count unchanged in Q3 2026.
Karyopharm Therapeutics made up ﹤0.01% of Activest Wealth Management's portfolio in Q3 2026, its #1015 holding.
Activest Wealth Management first reported a position in Karyopharm Therapeutics in Q2 2024 and has held it in 10 quarters since.
Activest Wealth Management's Karyopharm Therapeutics position peaked at $868 in Q2 2024.
13 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2026.

Based on Activest Wealth Management's 13F filing for Q3 2026, filed 15 Oct 2026.